4th Dimension Bioprocess

How to plan and succeed in
bioprocessing’s changing landscape.

Find out how we dramatically impact the timeline of producing clinical stage
drugs and reduce the time to deliver new, potentially life saving therapies to patients.

4th Dimension Bioprocess, Inc. is pleased to announce we’ve joined National Resilience, Inc.

www.resilience.com

We will continue and expand our efforts in continuous manufacturing as we join in the quest to change the future of medicine through manufacturing innovation

Our Vision

DESIGNED FOR SPEED. BUILT TO DELIVER.

Our aim is to streamline the delivery of new, lifesaving therapies to patients by providing high quality services enabled by robust continuous manufacturing platforms. 4^th Dimension Bioprocess, Inc, is a new breed of CDMO applying production line thinking, quality integration and the extensive use of automation to shorten your time to clinic. We’re creating the operational blueprint for the future.

Our Team

Lynne Frick

CEO

Expertise in start up management, corporate development, business & technology development, marketing & sales.

Tom Ransohoff

COO

Broad expertise in CMC, regulatory support of biopharmaceutical products; cGMP manufacturing; and management of technology-based start-up ventures.

Peter Rock

CFO

Experience with angel and VC funded start ups in biopharma, medical devices and tools.

Greg Zarbis-Papastoitsis

Advisor

Dr. Greg Zarbis-Papastoitsis is the EVP of Process and Manufacturing sciences at Ankyra Therapeutics, an immuno-oncology company.

4^th Dimension Bioprocess, Inc is establishing a unique Advanced Manufacturing Technology Sandbox™. The Sandbox is an industry-based community of practice and testbed for new equipment, software and approaches. Establishing a process development version of our Manufacturing platform, the MabFab™, an automated, single use, continuous bioprocessing manufacturing platform, we will innovate in areas necessary to accelerate biopharma’s wide adoption of intensified, continuous processes for biologics. These projects may include but are not limited to at-line and on-line assays, sensor integration, data analytics techniques to monitor CQAs throughout the process, the use of machine learning, statistical methods and eventually integrated product release testing, allowing for real time release and end to end automated 24/7 biomanufacturing capacity.